Amikacin-induced acute kidney injury in mechanically ventilated critically ill patients with sepsis

Abstract

In this retrospective cohort study, we aimed to evaluate the incidence, risk factors and outcomes of amikacin-induced acute kidney injury (AKI) in critically ill patients with sepsis. A total of 311 patients were included in the study. Of them, 83 (26.7%) had amikacin-induced AKI. In model 1, the multivariable analysis demonstrated concurrent use of colistin (OR 25.51, 95%CI 6.99–93.05, p< 0.001), presence of septic shock during amikacin treatment (OR 4.22, 95%CI 1.76–10.11, p=0.001), and Charlson Comorbidity Index (OR 1.14, 95%CI 1.02–1.28, p=0.025) as factors independently associated with an increased risk of amikacin-induced AKI. In model 2, the multivariable analysis demonstrated concurrent use of at least one nephrotoxic agent (OR 1.95, 95%CI 1.10–3.45; p=0.022), presence of septic shock during amikacin treatment (OR 3.48, 95%CI 1.61–7.53; p=0.002), and Charlson Comorbidity Index (OR 1.12, 95%CI 1.01–1.26; p=0.037) as factors independently associated with an increased risk of amikacin-induced AKI. In conclusion, before amikacin administration, the risk of AKI should be considered, especially in patients with multiple complicated comorbid diseases, septic shock, and those receiving colistin therapy.

KEYWORDS:

• Acute kidney injury
• amikacin
• colistin
• hospital mortality
• intensive care unit
• sepsis

Disclosure statement

No potential conflict of interest was reported by the authors.